AR060427A1 - Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares - Google Patents
Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovascularesInfo
- Publication number
- AR060427A1 AR060427A1 ARP070101523A ARP070101523A AR060427A1 AR 060427 A1 AR060427 A1 AR 060427A1 AR P070101523 A ARP070101523 A AR P070101523A AR P070101523 A ARP070101523 A AR P070101523A AR 060427 A1 AR060427 A1 AR 060427A1
- Authority
- AR
- Argentina
- Prior art keywords
- union
- alkyl
- hydroxy
- methoxy
- same
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 150000001412 amines Chemical class 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- -1 hydroxy, methoxy, ethoxy groups Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- QZLYKIGBANMMBK-UGCZWRCOSA-N androstane group Chemical group [C@@H]12CCC[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CCCC[C@]12C QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 239000001301 oxygen Substances 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 3
- 229910004679 ONO2 Inorganic materials 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000000468 ketone group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 2
- 229920002554 vinyl polymer Polymers 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 108091006112 ATPases Proteins 0.000 abstract 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 1
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06112598 | 2006-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060427A1 true AR060427A1 (es) | 2008-06-18 |
Family
ID=37268538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101523A AR060427A1 (es) | 2006-04-13 | 2007-04-11 | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8609644B2 (enExample) |
| EP (1) | EP2004668B1 (enExample) |
| JP (1) | JP5438503B2 (enExample) |
| KR (1) | KR101424046B1 (enExample) |
| CN (1) | CN101466725B (enExample) |
| AR (1) | AR060427A1 (enExample) |
| AU (1) | AU2007239518B2 (enExample) |
| BR (1) | BRPI0709943A2 (enExample) |
| CA (1) | CA2649175C (enExample) |
| EA (1) | EA015257B1 (enExample) |
| ES (1) | ES2405625T3 (enExample) |
| MX (1) | MX2008012942A (enExample) |
| PL (1) | PL2004668T3 (enExample) |
| PT (1) | PT2004668E (enExample) |
| TW (1) | TWI392682B (enExample) |
| WO (1) | WO2007118832A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168621B2 (en) | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
| US10174070B2 (en) | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| JP5290189B2 (ja) * | 2006-11-30 | 2013-09-18 | エンディース エルエルシー | ６−アルコキシアルキルエストラジオール誘導体およびその使用 |
| JP5738267B2 (ja) * | 2009-03-23 | 2015-06-24 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | タンパク尿、糸球体硬化、及び腎不全の治療に有用な５−β，１４−β−アンドロスタン誘導体 |
| WO2010149666A1 (en) | 2009-06-22 | 2010-12-29 | Medexis S.A. | Methods for treating neoplasia |
| WO2017149052A1 (en) * | 2016-03-02 | 2017-09-08 | Patheon Austria Gmbh Co. & Kg | Process and intermediates for the production of 17(20)-ene b-seco steroids |
| EP3962921B1 (en) * | 2019-04-27 | 2025-11-05 | Health Research, Inc. | Coumarin-modified androgens for the treatment of prostate cancer |
| FI3805243T3 (fi) * | 2019-10-09 | 2024-02-07 | Windtree Therapeutics Inc | Androstaanijohdannaisia, joilla on aktiivisuus puhtaina tai pääasiallisesti puhtaina SERCA2a:n stimulaattoreina, sydämen vajaatoiminnan hoitoon |
| CN111040012B (zh) * | 2019-12-27 | 2022-04-15 | 山东安弘制药有限公司 | 一种依西美坦螺环氧乙烷杂质的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB868303A (en) | 1956-09-08 | 1961-05-17 | Syntex Sa | New cyclopentanophenanthrene derivatives and process for the production thereof |
| BE589491A (enExample) * | 1959-04-10 | |||
| US3210386A (en) | 1961-01-09 | 1965-10-05 | Upjohn Co | 3-aminoethers of 3beta-hydroxy androstanes |
| DE1187236B (de) | 1961-03-28 | 1965-02-18 | Searle & Co | Verfahren zur Herstellung von 17beta-Aminosteroiden |
| GB1042292A (en) * | 1961-11-08 | 1966-09-14 | Organon Labor Ltd | 5ª‡-hydroxy-6ª‰-amino steroids and the preparation thereof |
| US3120515A (en) | 1962-05-31 | 1964-02-04 | Sterling Drug Inc | 5-cyano steroids, their preparation, and derivatives thereof |
| US5144017A (en) * | 1988-07-13 | 1992-09-01 | University Of Manitoba | Compounds that bind to digitalis receptor |
| US5522847A (en) * | 1993-06-18 | 1996-06-04 | Kalis; Amy G. | Pacifier with novelty electronic display |
| US5662685A (en) * | 1996-08-13 | 1997-09-02 | Uhler; Gary S. | Sound producing pacifier |
| DE19633349A1 (de) * | 1996-08-19 | 1998-02-26 | Sigma Tau Ind Farmaceuti | Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten |
| US6066161A (en) * | 1997-07-26 | 2000-05-23 | Parella; Nicole D. X. | Baby pacifier apparatus with remote control locator |
| DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
| DK1689410T3 (da) * | 2003-11-26 | 2008-09-08 | Bayer Schering Pharma Ag | Forebyggelse og behandling af hypertensive hjertesygdomme ved de selektive östrogener 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol og 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol |
-
2007
- 2007-03-26 TW TW096110303A patent/TWI392682B/zh not_active IP Right Cessation
- 2007-04-11 KR KR1020087027712A patent/KR101424046B1/ko not_active Expired - Fee Related
- 2007-04-11 CA CA2649175A patent/CA2649175C/en not_active Expired - Fee Related
- 2007-04-11 ES ES07727992T patent/ES2405625T3/es active Active
- 2007-04-11 EP EP07727992A patent/EP2004668B1/en active Active
- 2007-04-11 CN CN200780022229.3A patent/CN101466725B/zh not_active Expired - Fee Related
- 2007-04-11 BR BRPI0709943-6A patent/BRPI0709943A2/pt not_active Application Discontinuation
- 2007-04-11 JP JP2009504741A patent/JP5438503B2/ja not_active Expired - Fee Related
- 2007-04-11 AU AU2007239518A patent/AU2007239518B2/en not_active Ceased
- 2007-04-11 WO PCT/EP2007/053524 patent/WO2007118832A2/en not_active Ceased
- 2007-04-11 PT PT77279925T patent/PT2004668E/pt unknown
- 2007-04-11 US US12/295,497 patent/US8609644B2/en not_active Expired - Fee Related
- 2007-04-11 PL PL07727992T patent/PL2004668T3/pl unknown
- 2007-04-11 MX MX2008012942A patent/MX2008012942A/es active IP Right Grant
- 2007-04-11 AR ARP070101523A patent/AR060427A1/es not_active Application Discontinuation
- 2007-04-11 EA EA200870434A patent/EA015257B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804406A (en) | 2008-01-16 |
| CA2649175A1 (en) | 2007-10-25 |
| US8609644B2 (en) | 2013-12-17 |
| AU2007239518B2 (en) | 2012-03-15 |
| PT2004668E (pt) | 2013-04-30 |
| US20110053902A1 (en) | 2011-03-03 |
| ES2405625T3 (es) | 2013-05-31 |
| JP2009533392A (ja) | 2009-09-17 |
| KR20080111532A (ko) | 2008-12-23 |
| TWI392682B (zh) | 2013-04-11 |
| CA2649175C (en) | 2015-01-27 |
| HK1134821A1 (en) | 2010-05-14 |
| EP2004668A2 (en) | 2008-12-24 |
| AU2007239518A2 (en) | 2008-11-27 |
| WO2007118832A2 (en) | 2007-10-25 |
| KR101424046B1 (ko) | 2014-07-28 |
| EA200870434A1 (ru) | 2009-04-28 |
| MX2008012942A (es) | 2008-10-17 |
| CN101466725B (zh) | 2014-06-25 |
| PL2004668T3 (pl) | 2013-07-31 |
| EA015257B1 (ru) | 2011-06-30 |
| BRPI0709943A2 (pt) | 2011-08-02 |
| CN101466725A (zh) | 2009-06-24 |
| EP2004668B1 (en) | 2013-03-13 |
| JP5438503B2 (ja) | 2014-03-12 |
| WO2007118832A3 (en) | 2008-04-17 |
| AU2007239518A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060427A1 (es) | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares | |
| ES2564179T3 (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales | |
| ES2502790T3 (es) | Moduladores de la cinasa Aurora y método de uso | |
| ECSP088965A (es) | Derivados de 2-tioxantina que actúan como inhibidores de la mpo | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR059248A1 (es) | Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| AR075235A1 (es) | Derivados de indol como agentes anticancer. | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| PE20081838A1 (es) | Derivados de ester o amida de imidazolilo como moduladores del receptor glucocorticoide | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| AR076850A1 (es) | Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa. | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| ES2532084T3 (es) | Composiciones de topiramato y métodos para su uso | |
| PE20220376A1 (es) | Compuestos triciclicos y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |